We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SenesTech (SNES) New Alliance to Aid Expansion in South Africa
Read MoreHide Full Article
SenesTech, Inc. (SNES - Free Report) , a rodent fertility control company, recently partnered with Pathogens and Environmental Solutions (PES) of South Africa. They entered into a Development and Distribution Agreement for the commercialization of SenesTech’s ContraPest in South Africa.
South Africa being a prominentsub-Saharan economy has an active pest control industry focused on the agricultural and public health applications of pest control. Accordingly, we expect SenesTech’s ContraPest to witness strong market acceptance in this region.
More on the News
PES is a manufacturer and distributor of rodent pest control products, with a focus on broadening its offering by adding innovative products for integrated pest management. Per the agreement, PES will be responsible for gaining regulatory registration and all marketing and sales of ContraPest in South Africa.
SenesTech noted that the South African National Council of SPCAs (NSPCA) played an active role in getting the latest deal through. NSPCA, as an active adviser of SenesTech clearly articulated its support for rodent fertility control and ContraPest in particular. It deems PES as being an excellent partner for SenesTech in this project.
According to NSPA, PES has huge experience in securing registration and launching the commercialization of pest control products.
NSPCA is also working on recommending ContraPest to private and state entities and to assist with regulatory issues.
Image Source: Zacks Investment Research
Market Prospect
Going by a Research Dive report, in 2020, the worldwide market size for rodent control reached $3,209.8 million. It is anticipated to exhibit a CAGR of 4.9%, resulting in revenues of $4,659.7 million by 2028.
Per the report, the rodent control market is gaining popularity, banking on increasing awareness for clean quality of living as rodents, mosquitoes and ticks are carriers of infectious diseases.
Post the pandemic, when consciousness around health and hygiene is gaining significance across the globe, the latest development by SenesTech seems well-timed and strategic.
Price Performance
In the past year, SNES shares have declined 87.1% compared with the industry’s fall of 20.3%.
Zacks Rank and Key Picks
SenesTech currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the overall healthcare sector are Penumbra (PEN - Free Report) , Lantheus and Haemonetics (HAE - Free Report) . While Penumbra and Lantheus each sport a Zacks Rank #1 (Strong Buy), Haemonetics carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Penumbra’s stock has risen 175.7% in the past year. The Zacks Consensus Estimate for Penumbra’s earnings per share (EPS) has remained constant at $1.56 for 2023 and $2.56 for 2024 in the past 30 days.
PEN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 109.42%. In the last reported quarter, the company registered an earnings surprise of 109.09%.
The Zacks Consensus Estimate for Lantheus’ 2023 EPS has remained constant at $5.60 in the past 30 days. Shares of the company have improved 54.4% in the past year against the industry’s 19.8% decline.
LNTH’s earnings beat estimates in each of the trailing four quarters, the average surprise being 25.77%. In the last reported quarter, the company recorded an earnings surprise of 13.95%.
Estimates for Haemonetics’ EPS have increased from $3.29 to $3.55 for 2023 in the past 30 days. Shares of the company have increased 38% in the past year against the industry’s 19.8% decline.
HAE’s earnings beat estimates in each of the trailing four quarters, the average surprise being 12.21%. In the last reported quarter, Haemonetics delivered an earnings surprise of 13.24%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
SenesTech (SNES) New Alliance to Aid Expansion in South Africa
SenesTech, Inc. (SNES - Free Report) , a rodent fertility control company, recently partnered with Pathogens and Environmental Solutions (PES) of South Africa. They entered into a Development and Distribution Agreement for the commercialization of SenesTech’s ContraPest in South Africa.
South Africa being a prominentsub-Saharan economy has an active pest control industry focused on the agricultural and public health applications of pest control. Accordingly, we expect SenesTech’s ContraPest to witness strong market acceptance in this region.
More on the News
PES is a manufacturer and distributor of rodent pest control products, with a focus on broadening its offering by adding innovative products for integrated pest management. Per the agreement, PES will be responsible for gaining regulatory registration and all marketing and sales of ContraPest in South Africa.
SenesTech noted that the South African National Council of SPCAs (NSPCA) played an active role in getting the latest deal through. NSPCA, as an active adviser of SenesTech clearly articulated its support for rodent fertility control and ContraPest in particular. It deems PES as being an excellent partner for SenesTech in this project.
According to NSPA, PES has huge experience in securing registration and launching the commercialization of pest control products.
NSPCA is also working on recommending ContraPest to private and state entities and to assist with regulatory issues.
Image Source: Zacks Investment Research
Market Prospect
Going by a Research Dive report, in 2020, the worldwide market size for rodent control reached $3,209.8 million. It is anticipated to exhibit a CAGR of 4.9%, resulting in revenues of $4,659.7 million by 2028.
Per the report, the rodent control market is gaining popularity, banking on increasing awareness for clean quality of living as rodents, mosquitoes and ticks are carriers of infectious diseases.
Post the pandemic, when consciousness around health and hygiene is gaining significance across the globe, the latest development by SenesTech seems well-timed and strategic.
Price Performance
In the past year, SNES shares have declined 87.1% compared with the industry’s fall of 20.3%.
Zacks Rank and Key Picks
SenesTech currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the overall healthcare sector are Penumbra (PEN - Free Report) , Lantheus and Haemonetics (HAE - Free Report) . While Penumbra and Lantheus each sport a Zacks Rank #1 (Strong Buy), Haemonetics carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Penumbra’s stock has risen 175.7% in the past year. The Zacks Consensus Estimate for Penumbra’s earnings per share (EPS) has remained constant at $1.56 for 2023 and $2.56 for 2024 in the past 30 days.
PEN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 109.42%. In the last reported quarter, the company registered an earnings surprise of 109.09%.
The Zacks Consensus Estimate for Lantheus’ 2023 EPS has remained constant at $5.60 in the past 30 days. Shares of the company have improved 54.4% in the past year against the industry’s 19.8% decline.
LNTH’s earnings beat estimates in each of the trailing four quarters, the average surprise being 25.77%. In the last reported quarter, the company recorded an earnings surprise of 13.95%.
Estimates for Haemonetics’ EPS have increased from $3.29 to $3.55 for 2023 in the past 30 days. Shares of the company have increased 38% in the past year against the industry’s 19.8% decline.
HAE’s earnings beat estimates in each of the trailing four quarters, the average surprise being 12.21%. In the last reported quarter, Haemonetics delivered an earnings surprise of 13.24%.